A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

Roche (RHHBY) said Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for its highly-sensitive ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

A new type of off-the-shelf cell-based immunotherapy shows promise for B-cell lymphomas, and could make make future cellular ...

Basel: Roche has announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) ...